Search

Your search keyword '"Cances C"' showing total 201 results

Search Constraints

Start Over You searched for: Author "Cances C" Remove constraint Author: "Cances C"
201 results on '"Cances C"'

Search Results

1. A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy

3. Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1)

9. Variabilité phénotypique et corrélations génotype-phénotype des dystrophinopathies : contribution des banques de données

11. SMA CLINICAL DATA

12. SMA – OUTCOME MEASURES AND REGISTRIES

15. SMA - CLINICAL

16. SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES

17. SMA – THERAPY

18. Newly diagnosed and growing subependymal giant cell astrocytoma in adults with tuberous sclerosis complex: Results from the International TOSCA Study

19. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study

22. P.237Functional analyses and phenotype-genotype correlation studies in patients suspected of titinopathy

23. P.217Patterns of disease progression in patients with spinal muscular atrophy type 3 using the motor function measure

25. Mimetic staggered discretization of incompressible navier–Stokes for barycentric dual mesh

26. SMA THERAPIES I

27. SMA CLINICAL DATA, OUTCOME MEASURES AND REGISTRIES

28. SMA THERAPIES I

29. NEXT GENERATION SEQUENCING AND EXPERIMENTAL MYOLOGY

30. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy

31. Innovative home activity monitoring in non-ambulant patients with spinal muscular atrophy: a multicenter observational trial

32. Safety, tolerability and clinical efficacy of nusinersen in SMA type 1 older than 7 months: a prospective study

33. First experience of Nusinersen early access program in patients with spinal muscular atrophy type 1

34. Longitudinal data of the European prospective natural history study of patients with type 2 and 3 spinal muscular atrophy

35. Efficiency of next generation sequencing of a large panel of genes for diagnosis of children with myopathies and muscular dystrophies, especially for early and/or typical cases

38. Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: A national French retrospective study

39. RUFIPRAT: A retrospective study on the everyday clinical use of Rufinamide in children with refractory epilepsy

41. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: An observational cohort study

44. Baseline data from a European prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy – NatHis-SMA

45. Efficiency of targeted NGS on myopathies and muscular dystrophy genes: Importance of an optimized strategy of capture, sequencing, bioinformatic analyses and multidisciplinary approach for variants detection and interpretation

46. Feasibility of magneto-inertial motion analysis in non-ambulant patients with spinal muscular atrophy

48. Non-ambulant duchenne patients theoretically treatable by exon 53 skipping have severe phenotype

49. A European prospective study of the natural history of patients with type 2 and 3 spinal muscular atrophy

Catalog

Books, media, physical & digital resources